| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $987.3M | +66.7% |
| SG&A Expense | $195.0M | +100.5% |
| Operating Income | -$1.18B | -71.5% |
| Pre-tax Income | -$1.13B | -88.3% |
| Income Tax | $0 | +100.0% |
| Net Income | -$1.13B | -88.5% |
| EPS (Basic) | -$5.95 | -66.2% |
| EPS (Diluted) | -$5.95 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $383.7M | -29.3% |
| Short-term Investments | $1.64B | -6.0% |
| Current Assets | $2.08B | -10.9% |
| Total Assets | $2.35B | -8.0% |
| Current Liabilities | $290.4M | +77.2% |
| Total Liabilities | $723.2M | +146.7% |
| Stockholders' Equity | $1.63B | -28.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$897.7M | -61.0% |
| Capital Expenditures | $16.0M | +55.1% |
| Investing Cash Flow | $118.1M | +121.3% |
| Financing Cash Flow | $621.5M | -35.2% |
| Free Cash Flow | -$913.7M | -60.9% |
| -66.2% |